By Monika Trebo | September 22, 2016
Our recent work demonstrates the power of in vivo disease modeling, signaling circuit dissection with novel technologies such as Cytof and Mibi and target identification, e.g. ATAC seq, RNA seq and ChIP seq and integrating it with human disease with the purpose to make better drugs for fibrosing conditions such as liver cirrhosis, lung fibrosis, autoimmune diseases such as systemic sclerosis to excessive scaring. The combination of functional in vitro assays with in vivo disease modeling, analysis of signaling circuits, target identification with subsequent pharmacologic inhibition will offer the right candidate a great training environment and a unique set of scientific opportunities at Stanford.
Applicants should have a MD or PhD or equivalent doctoral degree with at least 3 years of proven research experience in Molecular Biology, Immunology or Leukemia/Cancer research. Financial support from an external funding source is advantageous, but not required. The ideal candidate should have a strong publication record and provide evidence of the ability to work independently and in a team. Payment is according to the Stanford University pay scale.
Please submit your complete application documents (including cover letter, CV with publication list and references) via email to: gwernig [at] stanford [dot] edu